Floatz logo

Oxodotreotide

Locally Advanced Paraganglioma

Fundación de investigación HMprotein_peptidePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Locally Advanced Paraganglioma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
M.D. Anderson Cancer Center
Phase 2CCC
Talzenna
National Cancer Institute (NCI)
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Guadecitabine
National Cancer Institute (NCI)
Phase 2CCC

View all 18 →

Same molecule, other indications

Oxodotreotide is also rated in:

pancreatic neuroendocrine tumorDormant
BBB
Indicative ·
75 / 100
View asset →
digestive system neuroendocrine neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
digestive system neuroendocrine tumor, grade 1/2Dormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →